Korlym

Korlym

Mifepristone (Korlym™, Corcept Therapeutics Inc.), was approved to manage hyperglycemia in patients with endogenous Cushing’s syndrome and type 2 diabetes mellitus or glucose intolerance who are not candidates for surgery or in whom surgical treatment has failed. This cortisol receptor blocker has potent antiprogestational properties and should never be used in pregnant women due to risk for pregnancy termination. Pregnancy must be excluded in women of reproductive age prior to initiation of therapy or if treatment is interrupted for more than 14 days.